Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00951977
Other study ID # DAIT RELIVE-04
Secondary ID
Status Completed
Phase N/A
First received July 31, 2009
Last updated March 10, 2017
Start date October 2009
Est. completion date June 2012

Study information

Verified date March 2017
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Kidney transplantation from living donors has been shown to carry many benefits over deceased donor transplantation. Because of benefits such as shorter waiting times and improved outcome for transplant recipients, living kidney donation accounts for an increasing number of kidney transplants nationwide. Most published studies about living kidney donation demonstrate that the procedure is safe, but they also emphasize concerns that long-term data on live donor outcomes are insufficient. The purpose of this study is to assess the long term outcomes and risks that may arise from living kidney donation.


Description:

Living donor transplants provide several advantages over deceased donor kidneys, including a shorter waiting time. Living donor grafts also appear to have a lower rate of delayed graft function and improved long-term recipient and graft survival. Most published studies of living kidney donation have supported that the donation process is relatively safe for the donor. However, these reports also emphasize concerns that comprehensive long-term data on U.S. live donor outcomes are insufficient. One concern is that current data may underestimate the true long-term morbidity and mortality of living kidney donation. Additionally, older studies might not apply to the current donor population that includes older and more obese individuals.

This is an observational study to look at the long term outcomes in living kidney donors. This study also seeks to find out if living kidney donors are at higher risk for certain conditions when compared to people of similar backgrounds who have not donated a kidney. Medical history, completed questionnaires, and blood and urine tests will be collected from donors and non donors. The compiled data from donors and non donors will be compared. Risks for diseases related to the kidney, heart, and blood vessels will be examined between the two groups. Quality of life and health insurance status will also be compared.

The study will be conducted in 2 phases. All donors who donated a kidney between 5 and 50 years ago at one of the three study transplant centers will be asked to take part in Phase 1. Phase 1 aims to collect limited medical information using a short questionnaire. Phase 2 will include Phase 1 donors who agree to further assessments and matched community control participants. Participants in Phase 2 will be asked to complete more in-depth questionnaires on health status and quality of life. Phase 2 also involves height, weight, and blood pressure measurements. Blood and urine will be collected for this study if the participant does not have the necessary tests within 3 years of study participation.

Seven thousand-eight hundred-sixty four (7864) previous kidney donors and about two thousand-five hundred (2500) control subjects will be asked to take part in this study. Participants will be recruited for this study over a 2.5.


Recruitment information / eligibility

Status Completed
Enrollment 7029
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Underwent a unilateral donor nephrectomy between 5 and 50 years ago; but no later than June 30, 2005

- Alive at the time of study recruitment

Exclusion Criteria:

- Inability to contact donor

Community Control Inclusion Criteria:

- Matched to donor as healthy subject with a medical encounter date within 5 years of the date of donation and alive at the time of study recruitment

- Same gender as donor

- Same race as donor

- Matched by age, not to differ by more than 2 years

- Matched by BMI, not to differ by more than 5 kg/m^2 (JHS only)

Community Control Exclusion Criteria:

- Inability to contact control participant

- Inability or unwillingness to provide informed consent

- Hypertension or identified Charlson comorbidity index variable diagnosed prior to or on the encounter date matched to the donor date of donation (REP only)

Study Design


Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States University of Minnesota Minneapolis Minnesota
United States Mayo Clinic Rochester Minnesota

Sponsors (3)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Health Resources and Services Administration (HRSA), National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (10)

Bieniasz M, Domagala P, Kwiatkowski A, Gozdowska J, Krzysztof O, Kieszek RA, Trzebicki J, Durlik M, Rowinski W, Chmura A. The assessment of residual kidney function after living donor nephrectomy. Transplant Proc. 2009 Jan-Feb;41(1):91-2. doi: 10.1016/j.transproceed.2008.08.160. — View Citation

Gross CR, Messersmith EE, Hong BA, Jowsey SG, Jacobs C, Gillespie BW, Taler SJ, Matas AJ, Leichtman A, Merion RM, Ibrahim HN; RELIVE Study Group.. Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study. A — View Citation

Hernández D, Alvarez A, Armas A, Rufino M, Porrini E, Torres A. [Metabolic syndrome and live kidney donor: is this syndrome a contraindication to donation?]. Nefrologia. 2009;29(1):20-9. doi: 10.3265/Nefrologia.2009.29.1.20.1.en.full.pdf. Review. Spanish. — View Citation

Horvat LD, Shariff SZ, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network.. Global trends in the rates of living kidney donation. Kidney Int. 2009 May;75(10):1088-98. doi: 10.1038/ki.2009.20. — View Citation

Jacobs CL, Gross CR, Messersmith EE, Hong BA, Gillespie BW, Hill-Callahan P, Taler SJ, Jowsey SG, Beebe TJ, Matas AJ, Odim J, Ibrahim HN; RELIVE Study Group.. Emotional and Financial Experiences of Kidney Donors over the Past 50 Years: The RELIVE Study. C — View Citation

Jowsey SG, Jacobs C, Gross CR, Hong BA, Messersmith EE, Gillespie BW, Beebe TJ, Kew C, Matas A, Yusen RD, Hill-Callahan M, Odim J, Taler SJ; RELIVE Study Group.. Emotional well-being of living kidney donors: findings from the RELIVE Study. Am J Transplant — View Citation

Messersmith EE, Gross CR, Beil CA, Gillespie BW, Jacobs C, Taler SJ, Merion RM, Jowsey SG, Leichtman AB, Hong BA; RELIVE Study Group.. Satisfaction With Life Among Living Kidney Donors: A RELIVE Study of Long-Term Donor Outcomes. Transplantation. 2014 Dec — View Citation

Noppakun K, Cosio FG, Dean PG, Taler SJ, Wauters R, Grande JP. Living donor age and kidney transplant outcomes. Am J Transplant. 2011 Jun;11(6):1279-86. doi: 10.1111/j.1600-6143.2011.03552.x. — View Citation

Rowinski W, Chmura A, Wlodarczyk Z, Ostrowski M, Rutkowski B, Domagala P, Dziewanowski K, Matych J, Durlik M, Grenda R. Are we taking proper care of living donors? A follow-up study of living kidney donors in Poland and further management proposal. Transplant Proc. 2009 Jan-Feb;41(1):79-81. doi: 10.1016/j.transproceed.2008.08.140. — View Citation

Taler SJ, Messersmith EE, Leichtman AB, Gillespie BW, Kew CE, Stegall MD, Merion RM, Matas AJ, Ibrahim HN; RELIVE Study Group.. Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades. Am J Transplant. 2013 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence and incidence of hypertension, proteinuria, renal disease, and anemia Since donation
Primary Prevalence and incidence of cardiovascular disease as manifested by myocardial infarction (MI), heart failure (HF), stroke, and CABG/PTCA Since donation
Primary Quality of life and insurance status Since donation
Secondary Incidence of hypertension, proteinuria, renal disease, anemia, and QOL in black and white donors. Since donation
Secondary Incidence of hypertension, proteinuria, renal disease, anemia, and QOL in donors with open nephrectomy and in donors with laparoscopic nephrectomy. Since donation
Secondary The operative morbidity in living kidney donors with open nephrectomy and in donors with laparoscopic nephrectomy. Since donation
Secondary Incidence of hypertension, proteinuria, renal disease, anemia, and QOL in standard living kidney donors and extended criteria donors. Since donation
Secondary Incidence of hypertension, proteinuria, renal disease, anemia, and QOL in donors more than 20 years since donation and in donors between 5 and 20 years since donation. Since donation
Secondary The identification of donor family characteristics that correlated with living kidney donor risk for morbidity and renal disease. Retrospective
Secondary Donor physical health and recipient post-transplant course as it correlates with positive QOL scores and negative QOL scores. Since donation
Secondary Identify the predictors and correlates of donors' quality of life outcomes Throughout study
Secondary Compare post-donation blood pressures, estimated glomerular filtration rate (GFR), urine protein levels and hemoglobin levels with those derived from population-based studies and matched community control participants After donation
Secondary Recipient outcomes for donors participating in the study and those who decline to participate. After donation
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03257410 - Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A